PIQUR Logo
X
Credits

Corporate Design, Web Design, Web Concept and Code:
SchwizerSchlatter GmbH, St.Gallen

Content:
IRF Communications AG, Zürich

Photography:
Till Forrer Photography, Zürich

PIQUR Logo
X
Disclaimer

No warranty and no liability
The material provided in this site is presented solely to improve public access to information about PIQUR Therapeutics AG.
PIQUR Therapeutics AG will make reasonable efforts to include accurate and current information, wherever possible, but makes no warranties or representations, expressed or implied, as to its accuracy or completeness. PIQUR Therapeutics AG will not be liable for any damages, including but not limited to special or consequential damages, that result from the use of, or the inability to use, the material contained in this site.
PIQUR Therapeutics AG may change the content of this site including the terms that govern the use of this site at any time without prior notice but does not assume any responsibility to update the information provided herein.

Forward looking information
Some of the statements on this site are forward looking. Such statements are inherently subject to known and unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of PIQUR Therapeutics AG and affiliates to be materially different from those expected or anticipated in the forward-looking statements.

PIQUR Therapeutics AG has no responsibility to update the forward-looking statements contained in this site to reflect events or circumstances occurring after the date of publication. You must not rely on this information for investment decisions.

Links to third party sites
Links to third party sites are provided for convenience only, and the inclusion of any links does not imply endorsement by PIQUR Therapeutics AG. The linked sites are not under control of PIQUR Therapeutics AG, and PIQUR Therapeutics AG disclaims any liability for all third party information and the use of it.

Restrictions on use and submissions
The contents of this site are owned and controlled by PIQUR Therapeutics AG. No use of any of these may be made without the prior written consent of PIQUR Therapeutics AG. All submissions communicated to PIQUR Therapeutics AG through this site shall be and remain PIQUR Therapeutics AG’s property. PIQUR Therapeutics AG will be entitled to use your submission for any commercial or other purpose whatsoever without paying any compensation to you. PIQUR Therapeutics AG will be under no obligation to treat your submission as confidential nor to respond to it. The pictures displayed on this website are subject to copyrights and may not be downloaded, copied, distributed or otherwise be used without prior permission of PIQUR Therapeutics AG.

Applicable law and jurisdiction
These terms shall be construed, enforced and performed in accordance with the substantive laws of Switzerland, without reference to the principles of conflicts of laws. The place of jurisdiction is Basel, Switzerland. PIQUR Therapeutics AG makes no representation that any information, materials or functions included are appropriate for use in any other jurisdiction. If you access this site you do so on your own initiative and are responsible for compliance with applicable local laws and regulations.

Address
Directions by car
Directions from railway station Basel Bad Bf
Directions from the railway station Basel SBB
How to find us
Show Map
Address

Address:
PIQUR Therapeutics AG
Hochbergerstrasse 60C
CH-4057 Basel
Switzerland
T +41 61 633 29 29
info@piqur.com

Media Contact:
IRF Communications AG
Daniel Piller, Partner
Raemistrasse 4
P.O. Box
CH-8024 Zürich
Switzerland
daniel.piller@irfcom.ch
www.irfcom.ch

X
Directions by car

Highway A2 exit 1, along in direction Stücki/Kleinhüningen, you can drive up the ramp of the big grey building called Stücki Businesspark (next to the COOP gas station) and park right in front of the building or on the parking below.

X
Directions from railway station Basel Bad Bf

Bus no. 36 in direction Kleinhüningen, get off at bus-station «Hochbergerstrasse» (approx. 4 min.), follow driveway Hochbergerstrasse, after 150m on your right hand side you will see a big grey building called Stücki Business Park, go up the ramp and you find the entrance «C»

X
Directions from the railway station Basel SBB

Tram no. 2 in direction Eglisee, get off at tram-station «Basel Badischen Bahnhof» (approx. 10 min.), change and take bus no. 36 in direction Kleinhüningen, bus-stop «Hochbergerstrasse» (approx. 5 min.), follow driveway Hochbergerstrasse, after 150m on your right hand side you will see a big grey building called Stücki Business Park, go up the ramp and you find the entrance «C».

X
How to find us

PIQUR is located close to the centre of Basel on the north bank of the River Rhine, a few minutes from the borders of France and Germany. It is easily accessible by public transport from the two main railway stations and the airport.

The premises of PIQUR Therapeutics AG are located in the Technology Park Basel in the Stücki Business Park.

X
Contact
Intellectual Property
Science
Pipeline
Intellectual Property

PIQUR’s patent portfolio protects and covers a large area of lipid kinase and mTOR inhibitor patent space. PIQUR has created an intellectual property strategy that maximizes the protection of its technologies, knowhow and research areas of current and future interest. PIQUR’s differentiation against its peers is the outstanding industry expertise, the level of innovation with its unique, proprietary fragment and scaffold libraries and their best-in-class products with novel, balanced, dual-acting PI3K/mTOR inhibitors that fully address the given challenges, meeting therapeutic, tolerance and galenic needs.

Science

One in every 2 men and one in every 3 women, living in the developed world, will develop cancer at some stage in their lives. In 2012, cancer accounted for 8 million deaths worldwide. Each cancer treatment remains a case-by-case battle, with a limited panel of therapeutic options available. Given the relatively small number of cancer treatments available today, the emergence of resistance usually means a poor prognosis. Thus, there is a tremendous need for new targeted therapies, based on new mechanisms of action and accompanied by a range of biomarker diagnostics for diagnosis, patient selection, therapy monitoring and follow up.

PI3K/mTOR-Pathway

The PI3K-Akt-mTOR pathway is one of the three major cancer signalling pathways (Nature Rev. 2008). The PI3K/Akt/mTOR signalling pathway plays a critical role in the regulation of cancer cell growth, survival, and proliferation. The deregulation of this pathway is initiated by genetic mutations and amplifications, and is thought to be one of the most frequently mutated pathways in cancer. (Hennessy et al., 2005, Nat. Rev. Drug Discovery; Liu et al., 2009, Nat. Rev. Drug Discovery; Zoncu, R. et al., 2011, Nat. Rev. Mol. Cell Biol.).

Pipeline

PIQUR seeks to develop and market next generation medications for the treatment of cancer. To achieve this goal, PIQUR continues to expand on its strong product pipeline and has developed several proprietary methods for drug screening and identification

PIQUR has already identified a number of compounds that have desirable drug properties, both from a biological and a manufacturing perspective, forming the backbone of our pipeline.

PQR309: PIQUR’s lead compound, PQR309, is a novel, potent small molecule with strong, balanced pan-PI3K/mTOR selectivity. PQR309 compares favourably to current and clinically most advanced pan-PI3K inhibitors with respect to the off-target effects. PQR309 showed activity in different aggressive cancer cell lines inhibiting the PI3K pathway. In January 2014, PIQUR launched the clinical Phase 1 study in Europe with the PQR309 that was successfully concluded in Q2/2015. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity in two advanced solid tumors patients with PI3K/mTOR alterations.

In addition to PQR309, PIQUR has several other compounds in preclinical development and late stage research in oncology, ophthalmology, dermatology and CNS disorders.